Gleamer raises €27m in Series B funding round
French AI-powered radiography diagnostics specialist Gleamer SAS has raises €27m in Series B round to expand its portfolio and accelerate its expansion.
ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2082 entries already.
French AI-powered radiography diagnostics specialist Gleamer SAS has raises €27m in Series B round to expand its portfolio and accelerate its expansion.
Exosomes are extracellular vesicles ranging from 30 to 150 nm in diameter that are released from various types of cells, including tumor cells. They can induce apoptosis, modulate the immune system, and function as biomarkers for diagnosis. In addition, as an important component of cell-to-cell communication, exosomes can regulate the tumor microenvironment and are involved in the development, progression, and metastasis processes of numerous cancers1,2.
Multi-omics diagnostics specialist Centogene NV has received €30m to form a joint venture with PIF-owned pharmaceutical company Lifera in Saudi-Arabia.
French cell and gene therapy manufacturing specialist Astraveus SAS had raises €16.5m in seed money to advance its automated, microfluidic Cell and Gene Therapy manufacturing platform.
Breaking news from biotechnology and the German stock market are in the focus of the new issue of BIOTECH Insight, the newsletter of Deutsche Börse AG.
Tilos marks the first island to achieve 100% diversion from landfill with an 87% recycling rate.
Santhera Pharmaceuticals Holding has exclusively granted the rights to commercialise its Duchenne muscular dystrophy drug vamorolone in North America to Catalyst Pharmaceuticals Inc.
BioSenic SA has suspended its Phase II proof-of-concept trial on fracture healing with its allogeneic cell therapy ALLOB.
Swedish personalised immunotherapy specialist Neogap Therapeutics AB has acquired the remaining shares of its subsidiary, TCER Oncology AB through two new shareholders.
An international research team headed by Pablo Guardado-Calvo at Institut Pasteur Paris has demonstrated evaluated antibody efficacy against lethal hantaviruses.